News | February 18, 2022
AptarGroup reported 2021 sales at US $3.23 billion
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
According to ICMR, the upgraded OmiSure RT-PCR test for Covid-19 successfully detects all sub-types of Omicron that are currently prevalent in India
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Subscribe To Our Newsletter & Stay Updated
